Notice Pursuant to the National Cooperative Research and Production Act of 1993-Rapid Response Partnership Vehicle

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Justice Antitrust Division ( printed page 82631) Notice is hereby given that, on July 11, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Rapid Response Partnership Vehicle (“RRPV”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Esperovax, Inc., Plymouth, MI; Genomic Expression, Inc., Beverly, MA; ID Biologics, Inc., Nashville, TN; MPS Medical, Inc., Brea, CA; QuidelOrtho Corp., San Diego, CA; Sinergium Biotech S.A., Buenos Aires, ARGENTINA; Somatek, San Diego, CA; True Diagnostics, Inc., Carlsbad, CA; VaxSyna, Inc., Franklin, NH; Burrell International Group LLC, Washington, DC; Cellular Technology, Ltd., Shaker, OH; QIAGEN LLC, Germantown, MD; RAIsonance, Inc., Greenwood Village, CO; Canaria Technologies Pty, Ltd., Brisbane, AUSTRALIA; Elarex, Inc., Burlington, CANADA; Gila Diagnostics, Inc., Phoenix, AZ; IIT Research Institute, Chicago, IL; ImmunoServ, Cardiff, UNITED KINGDOM; OraSure Technologies, Inc., Bethlehem, PA; Vaccine Company, Inc., Bethesda, MD; Visby Medical, Inc., San Jose, CA; Global Life Science Solutions USA LLC dba Cytiva, Marlborough, MA; Pathway Policy Grou…